Mallinckrodt plc (MNK)

Overview

Mallinckrodt plc is a pharmaceutical company that specializes in developing, manufacturing, marketing, and distributing specialty pharmaceutical products and therapies globally. The company operates through two main segments: Specialty Brands, focusing on innovative branded pharmaceutical products for various autoimmune and rare diseases, and Specialty Generics, dedicated to producing specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt, established in 1867 with its headquarters in Dublin, Ireland, has a broad geographical presence, extending its market across the United States, Europe, the Middle East, Africa, and other international regions. The company’s dedication to addressing complex health conditions has led to collaborations, such as with Silence Therapeutics plc, to pioneer in ribonucleic acid interference (RNAi) drug targets, showcasing Mallinckrodt’s commitment to leading advancements in pharmaceutical therapies.

Products and Services

• Acthar Gel:

A repository corticotropin injection used in the treatment of numerous conditions, including rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, and other severe acute and chronic Allergic and inflammatory diseases. Acthar Gel highlights Mallinckrodt's dedication to providing solutions for autoimmune and rare diseases.

• INOmax:

A vasodilator designed to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation in neonatal patients requiring respiratory support. INOmax demonstrates Mallinckrodt’s commitment to neonatal and respiratory critical care therapies.

• Therakos Photopheresis:

An immunotherapy treatment platform for conditions requiring extracorporeal photopheresis. This innovative treatment underscores the company's focus on pioneering immune therapy solutions.

• Amitiza:

A medication prescribed for the treatment of constipation, showcasing Mallinckrodt’s offerings in the gastrointestinal product space.

• StrataGraft:

Developed for the treatment of adults with deep partial-thickness burns, StrataGraft represents Mallinckrodt’s efforts in providing solutions for critical care in severe burn injuries.

• Terlipressin:

Currently under development for treating hepatorenal syndrome, Terlipressin indicates Mallinckrodt’s ongoing research and development efforts towards addressing rare and life-threatening conditions.

• SLN 501:

A ribonucleic acid silencing therapy under development, showcasing Mallinckrodt’s venture into RNAi technology aimed at the treatment of various diseases through gene silencing mechanisms.

Besides these branded products, Mallinckrodt also manufactures and markets a range of specialty generic drugs and active pharmaceutical ingredients, catering to numerous healthcare needs and emphasizing the company’s diversified approach in the pharmaceutical industry. The company’s branded products are marketed directly to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies, ensuring a wide-reaching impact on healthcare delivery.